GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining
This article was originally published in The Pink Sheet Daily
Executive Summary
Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.